期刊文献+

OIP5基因在肾癌细胞中的作用及索拉非尼对Raf1/OIP5通路的影响

Role of OIP5 gene in renal cancer and effect of Sorafenib on Raf1/OIP5 pathway
下载PDF
导出
摘要 目的探讨OIP5基因在肾癌中的作用机制及索拉非尼对Raf1/OIP5通路的影响。方法利用CCK-8及细胞迁移实验来检测上调OIP5基因前后细胞的增殖活力及迁移能力,并利用侵袭实验来检测下调OIP5基因前后细胞的侵袭能力。在786-O细胞中下调Raf1基因后,检测OIP5基因的RNA及蛋白的表达情况。利用5μmol/L和10μmol/L的索拉非尼作用于786-O细胞48h后,检测Raf1和OIP5基因的表达情况。结果上调OIP5基因后786-O细胞的增殖活力及迁移能力都明显增强。下调OIP5基因后786-O细胞的侵袭能力明显减弱。下调Raf1基因后,OIP5基因的RNA及蛋白水平都明显下调。利用5μmol/L和10μmol/L的索拉非尼作用于786-O细胞48h后,Raf1及OIP5的表达均明显下调。结论 OIP5基因在肾癌中起到类似癌基因的作用,索拉非尼可以通过Raf1/OIP5通路发挥其抗肿瘤的作用。 Objective To explore the role of OIP5 gene in renal cancer and the effect of Sorafenib on Raf1/OIP5 pathway.Methods Before and after up-regulation of OIP5 gene,cell proliferation and migration were detected with CCK-8 and cell migration assays,and cell invasion was tested with invasion assay.After down-regulation of Raf1 gene,the RNA and protein expression of OIP5 gene in786-O cells were determined.After 786-O cells were treated with 5μmol/L and 10μmol/L Sorafenib for 48 hours,the expression of Raf1 and OIP5 genes was tested.Results The proliferation and migration of 786-O cells were obviously enhanced after up-regulation of OIP5 gene.In addition,the invasive ability of 786-O cells was significantly decreased after down-regulation of OIP5 gene.After down-regulation of Raf1 gene in 786-O cells,the RNA and protein expression of OIP5 gene were dramatically decreased.After 786-O cells were treated with 5μmol/L and10μmol/L Sorafenib for 48 hours,the expression of Raf1 and OIP5 genes was obviously decreased.Conclusion OIP5 gene plays a oncogenil role in the progression of renal cancer.Sorafenib can inhibit the development of renal cancer through Raf1/OIP5 pathway.
作者 宫满成 董文静 丘少鹏 袁润强 GONG Man-cheng DONG Wen-jing QIU Shao-peng YUAN Run-qiang(Department of Urology Department of Oncology, People's Hospital of Zhongshan, Zhongshan 528403 Department of Urology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China)
出处 《现代泌尿外科杂志》 CAS 2017年第6期467-471,共5页 Journal of Modern Urology
基金 广东省医学科研基金项目(No.A2016058) 中山市科技计划项目(No.2015B1012) 中山市医学科研基金项目(No.2016J040)
关键词 肾癌 OIP5 基因 索拉非尼 renal cancer OIP5 gene Sorafenib
  • 相关文献

参考文献1

二级参考文献39

  • 1Jimeno A,Hidalgo M.Multitargeted therapy:can promiscuity be praised in an era of political correctness?[J].Crit Rev Oncol Hematol,2006,59(2):150-158.
  • 2De Jonge MJ,Verweij J.Multiple targeted tyrosine kinase inhibition in the clinic:all for one or one for all?[J].Eur J Cancer,2006,42(10):1351-1356.
  • 3Keith CT,Borisy AA,Stockwell BR.Multicomponent therapeutics for networked systems[J].Nat Rev Drug Discov,2005,4(1):71-78.
  • 4Arora A,Scholar EM.Role of tyrosine kinase inhibitors in cancer therapy[J].J Pharmacol Exp Ther,2005,315(3):971-979.
  • 5Blume-Jensen P,Hunter T.Oncogenic kinase signalling[J].Nature,2001,411(6835):355-365.
  • 6Konecny GE,Pegram MD,Venkatesan N,et al.Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells[J].Cancer Res,2006,66(3):1630-1639.
  • 7Burris HA,Hurwitz HI,Dees EC,et al.Phase Ⅰ safety,pharmacokinetics,and clinical activity study of lapatinib (GW572016),a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases,in heavily pretreated patients with metastatic carcinomas[J].J Clin Oncol,2005,23(23):5305-5313.
  • 8Hanrahan EO,Heymach JV.Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer[J].Clin Cancer Res,2007,13(15):4617-4622.
  • 9Arnold AM,Seymour L,Smylie M,et al.Phase Ⅱ study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy:National Cancer Institute of Canada Clinical Trials Group Study BR.20[J].J Clin Oncol,2007,25(27):4278-4284.
  • 10Eskens FA,Mom CH,Planting AS,et al.A phase Ⅰ dose escalation study of BIBW 2992,an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on,2-week off schedule in patients with advanced solid tumours[J].Br J Cancer,2008,98(1):80-85.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部